Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Boehringer Ingelheim
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03099174CT.gov This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer | — | Completed | — | — | — |
NCT02145741CT.gov Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours | — | Completed | — | — | — |
NCT02123823CT.gov BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01403974CT.gov Phase I Trial of BI 836845 for Various Solid Cancer | — | Completed | — | — | — |
NCT01317420CT.gov Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Xentuzumab (this asset) | Boehringer Ingelheim | P1 | CCC · 52 |
| Panitumumab | Astellas Pharma Inc | P2 | BB |
| Irinotecan | Mirati Therapeutics Inc. | P4 | BB |
| Nivestim | Ankara Etlik City Hospital | P2 | BB |
| Dexasone | Hellenic Society of Hematology | P3 | BB |
| Feladilimab | GlaxoSmithKline | P2 | BB |
| Carboplatin | Bristol-Myers Squibb | P3 | BB |
| Pralsetinib, Trans- | Seoul National University Bundang Hospital | P3 | BB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Xentuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Neoplasm | — | P2 | CCC · 53 |
| Castration-Resistant Prostate Carcinoma | — | P1 | CC · 44 |
| Non-Small Cell Lung Carcinoma | — | P1 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Xentuzumab in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/xentuzumab-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →